Skip to main content

Table 1 Clinical characteristics

From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

  Total Training cohort   Validation cohort   P
   Total Patients, NO. (%) P Total Patients, NO. (%) P  
Characteristic    A+T T   A+T T  
NO. of patients 318 176 88 88   142 71 71   
Median age, years (range) 56 (28–83) 56 (28–83) 55.75 (28–74) 57 (31–84) 0.166   56 (26–75) 57 (33–80) 0.412 0.735
Sex
 Male 128 (40.2%) 67 (38.1%) 36 (40.9%) 31 (35.2%) 0.535 61 (43%) 30 (42.3%) 31 (43.7%) 0.768 0.744
 Female 190 (59.8%) 109 (61.9%) 52 (59.1%) 57 (64.8%)   81 (57%) 41 (57.7%) 40 (56.3%)   
Smoking history
 Never 232 (73%) 121 (68.8%) 66 (75%) 55 (62.5%) 0.103 111 (78.2%) 56 (78.9%) 55 (75%) 0.925 0.417
 Former 86 (27%) 55 (31.2%) 22 (25%) 33 (37.5%)   31 (21.8%) 15 (21.1%) 16 (25%)   
Pathology
 Adenocarcinoma 318 (100) 176 (100%) 88 (100%) 88 (100%) 1 142 (100%) 71 (100%) 71 (100%) 1 1
 Squamous carcinoma 0 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%) 0 (0%)   
ECOG performance status
 0–1 303 (94.3%) 172 (97.7%) 86 (97.7%) 86 (97.7%) 1 131 (92.2%) 65 (91.5%) 66 (92.9%) 0.975 0.896
 2 15 (5.7%) 4 (2.3%) 2 (2.3%) 2 (2.3%)   11 (7.3%) 6 (8.5%) 5 (7.1%)   
Brain metastasis
 Yes 102 (32%) 58 (32.9%) 28 (31.8%) 30 (34.1%) 0.862 44 (30.9%) 23 (32.4%) 21 (29.5%) 0.769 0.711
 No 216 (68%) 118 (67.1%) 60 (68.2%) 58 (65.9%)   98 (69.1%) 48 (61.6%) 50 (70.5%)   
Bone metastasis
 Yes 160 (50.3%) 88 (50%) 47 (53.4%) 41 (46.6%) 0.451 72 (50.7%) 34 (47.9%) 38 (53.5%) 0.379 0.637
 No 158 (49.7%) 88 (50%) 41 (46.6%) 47 (53.4%)   69 (49.3%) 37 (52.1%) 33 (46.5%)   
Liver metastasis
 Yes 40 (12.5%) 21 (11.9%) 12 (13.6%) 9 (10.2%) 0.643 19 (13.4%) 9 (12.6%) 10 (14.1%) 0.563 0.677
 No 278 (87.5%) 155 (88.1%) 76 (86.4%) 79 (89.8%)   123 (86.6%) 62 (87.4%) 61 (85.9%)   
Stage
 IIIa/IIIb 9 (2.8%) 5 (2.8%) 1 (1.1%) 4 (4.5%) 0.368 4 (2.8%) 2 (1.1%) 2 (4.5%) 1 0.614
 IV 309 (97.2%) 171 (97.2%) 87 (98.9%) 84 (95.5%)   138 (97.2%) 69 (98.9%) 69 (95.5%)